10b5-1 SALE PLAN AGREEMENT10b5-1 Sale Plan Agreement • October 6th, 2023 • KKR Credit Advisors (US) LLC • New York
Contract Type FiledOctober 6th, 2023 Company JurisdictionThis letter agreement (this “Letter Agreement”) confirms the terms and conditions under which KKR FSK Aggregator (UNLEV) L.P., and KKR FSK II Aggregator (UNLEV) L.P., each a limited partnership organized under the laws of the state of Delaware (each a “Seller”), hereby establishes a plan (the “Plan”) to sell shares of common stock, par value $0.001 (the “Securities”), of FS KKR Capital Corp. (the “Issuer”), and under which J.P. Morgan Securities LLC (“JPMS”) will act as its exclusive agent to execute the Plan. This Letter Agreement replaces the letter agreement among the Sellers and JPMS dated September 9, 2022, which is hereby terminated effective immediately.
10b5-1 SALE PLAN AGREEMENT10b5-1 Sale Plan Agreement • July 16th, 2020 • Vifor (International) LTD • Pharmaceutical preparations • New York
Contract Type FiledJuly 16th, 2020 Company Industry JurisdictionThis letter agreement (this “Letter Agreement”) confirms the terms and conditions under which Vifor (International) Ltd, an entity formed under the laws of Switzerland (the “Seller”), hereby establishes a plan (the “Plan”) to sell shares of common stock, par value $$0.001 (the “Securities”), of Chemocentryx, Inc. (the “Issuer”), and under which J.P. Morgan Securities LLC (“JPMS”) will act as its exclusive agent to execute the Plan.
10b5-1 SALE PLAN AGREEMENT10b5-1 Sale Plan Agreement • February 26th, 2021 • CBEP Investments, LLC • Telephone communications (no radiotelephone) • New York
Contract Type FiledFebruary 26th, 2021 Company Industry JurisdictionThis letter agreement (this “Letter Agreement”) confirms the terms and conditions under which CBEP Investments, LLC, a limited liability company organized under the laws of the state of Delaware (the “Seller”), hereby establishes a plan (the “Plan”) to sell shares of common stock, par value $ 0.0001 (the “Securities”), of GTT Communications, Inc. (the “Issuer”), and under which J.P. Morgan Securities LLC (“JPMS”) will act as its exclusive agent to execute the Plan.